Rival to give Ventracor a transfusion Date 7/11/2007 Source The...

Rival to give Ventracor a transfusion

Date 7/11/2007

Source The Australian Financial Review --- Page: 31
The US Food & Drug Administration is poised to approve the HeartMate 2product of heart device maker Thoratec. Peter Crosby, the CEO ofAustralian-listed Ventracor, believes that the entire cardiac technology sectorwill enjoy a higher growth profile if Thoratec's product is given the greenlight. Ventracor is undertaking US clinical trials of its cardiac implant, andis aiming to receive US regulatory approval for the device by 2010. Ventracorshares eased $A0.01 on 6 November 2007, closing at $A0.735